Acceleron Pharma Aktie - XLRN

Professionelle Tools für Privatanleger.

Premium

Current Price

178,75

Gebot

179,92

Fragen

179,91

Volumen

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Handelsende

178,75

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer

Believes Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process Remains Confident in Company’s Standalone...

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer

Believes Now Is the Wrong Time to Cash out of Acceleron, Given Company’s Strong Momentum and Near-Term Inflection Point Coming from Phase 3...

Acceleron Reports Third Quarter 2021 Financial Results

- Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL®...

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

Remains Opposed to Sale of Acceleron to Merck at Current Price and Plans Not to Tender Its Shares Believes Company Has Strong Momentum and...

Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales

- Acceleron expects to report approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of...

Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma

Proposed 38% Premium Ranks Much Lower Than Average Premium of Approximately 89% for Comparable Biopharma Transactions since 2020 Believes...

Acceleron Reports Second Quarter 2021 Financial Results

- Highlighted ongoing and planned trials in rare pulmonary diseases and presented vision and strategy for long-term growth at June R&D Day...

Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales

- Acceleron expects to report approximately $25.6 million in royalty revenue for Q2 2021 from approximately $128 million in net sales of...

Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 5, 2021 at 5:00 p.m. EDT to...

Bristol Myers Squibb & Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults ...

Results showed treatment with Reblozyl plus best supportive care improved anemia in 77% of patients compared to placebo Reblozyl was generally...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

XLRN - Frequently Asked Questions (FAQ)

What is the current Acceleron Pharma share price?

The current share price of Acceleron Pharma is US$ 178,75

What is the 1 year trading range for Acceleron Pharma share price?

Acceleron Pharma has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
AAGRAfrican Agriculture Holdings Inc	US$ 0,00 (0,00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 0,00 (0,00%)	0
AADIAadi Bioscience Inc	US$ 0,00 (0,00%)	0
AACGATA Creativity Global	US$ 0,00 (0,00%)	0
AACBUArtius II Acquisition Inc	US$ 0,00 (0,00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0,00 (0,00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 0,00 (0,00%)	0
AADIAadi Bioscience Inc	US$ 0,00 (0,00%)	0
AACGATA Creativity Global	US$ 0,00 (0,00%)	0
AACBUArtius II Acquisition Inc	US$ 0,00 (0,00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0,00 (0,00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 0,00 (0,00%)	0
AADIAadi Bioscience Inc	US$ 0,00 (0,00%)	0
AACGATA Creativity Global	US$ 0,00 (0,00%)	0
AACBUArtius II Acquisition Inc	US$ 0,00 (0,00%)	0

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Acceleron Pharma Inc (XLRN)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

XLRN Neueste Nachrichten

Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer

Acceleron Reports Third Quarter 2021 Financial Results

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales

Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma

Acceleron Reports Second Quarter 2021 Financial Results

Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales

Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021

Bristol Myers Squibb & Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults ...

XLRN - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Acceleron Pharma Inc (XLRN) Börsenkurse

Acceleron Pharma Inc (XLRN)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

XLRN Neueste Nachrichten

Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer

Acceleron Reports Third Quarter 2021 Financial Results

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales

Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma

Acceleron Reports Second Quarter 2021 Financial Results

Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales

Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021

Bristol Myers Squibb & Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults ...

XLRN - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS